Renaissance Technologies LLC Boosts Stock Position in Lipocine Inc. (NASDAQ:LPCN)

Renaissance Technologies LLC increased its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the period. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Dimensional Fund Advisors LP purchased a new position in Lipocine during the second quarter valued at $98,000. 9.11% of the stock is owned by institutional investors.

Lipocine Stock Down 1.2 %

Shares of LPCN opened at $5.14 on Friday. Lipocine Inc. has a 52-week low of $2.31 and a 52-week high of $11.79. The stock has a market cap of $27.49 million, a PE ratio of -3.01 and a beta of 1.22. The firm’s fifty day moving average is $4.26 and its two-hundred day moving average is $5.59.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The company had revenue of $0.09 million for the quarter. As a group, research analysts anticipate that Lipocine Inc. will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on LPCN. StockNews.com cut shares of Lipocine from a “buy” rating to a “hold” rating in a research note on Saturday, September 28th. Alliance Global Partners initiated coverage on Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.

Lipocine Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.